

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:


1. (Withdrawn-previously presented): A method for treatment and/or prevention of a disease due to constriction or vasodilation of blood vessels, which comprises administering to a mammal an effective dose of the compound according to claim 10.

2. (Withdrawn-previously presented): The method according to claim 1, wherein the disease due to constriction or vasodilation of blood vessels is selected from cerebrovascular spasmodic disorder, cardiovascular spasmodic disorder, hypertension, renal disease, cardiac infarction, cardiac angina, arrhythmia, facilitation of the portal blood pressure, varicosity, chronic headache, haemorrhoid and congestive disorder.

3. (Withdrawn- previously presented): The method according to claim 2, wherein the blood vessel is a cerebral artery, a renal artery, a coronary artery, a pulmonary artery, an aorta or a vein.


4-9. (Canceled).

10. (currently amended): A compound represented by formula (I):



wherein:

A represents



wherein R¹ represents a substituent,

R² represents hydroxy or C1-6 ~~alkoxy~~alkoxy,

R³ represents a substituent, and

r represents 0 or an integer of 1-4,

X represents a single bond,

Y represents -CO-~~or~~-CS-,

Z represents a nitrogen atom optionally substituted with C1-6 ~~alkoxy~~alkoxy,

B represents a cyclic group optionally with a substituent(s), or a pharmaceutically acceptable salt thereof.

11-19. (Canceled).

20. (previously presented): The compound according to claim 10, wherein R² is hydroxy.

21. (Canceled).

22. (Original): The compound according to claim 20, wherein R¹ is a chain substituent.

23. (Canceled).

24. (Original): The compound according to claim 22, wherein the chain substituent is alkyl.

25. (Original): The compound according to claim 22, wherein the chain substituent is substituted alkyl.


26. (Canceled).

27. (Original): The compound according to claim 24, wherein the cyclic group optionally with a substituent(s) represented by B is an aromatic ring.

28. (Canceled).

29. (Original): The compound according to claim 27, wherein the cyclic group is substituted with 1 or at least 2 substituent(s).

30. (Original): The compound according to claim 29, wherein the cyclic group with at least 2 substituents is



wherein B¹ represents a carbon ring of an aromatic ring,

R¹¹ and R¹² each represents a substituent,

m represents an integer of 1-4, and

the other symbols have the same meanings as those mentioned above.


32-43. (Canceled).

44. (Previously Presented): The compound according to claim 10, wherein the cyclic group optionally with a substituent(s) represented by B is an aromatic ring.

45. (Canceled).

46. (Original): The compound according to claim 44, wherein the cyclic group is substituted with 1 or at least 2 substituent(s).

47. (Original): The compound according to claim 46, wherein the cyclic group with at least 2 substituents is



wherein B¹ represents a carbon ring of an aromatic ring,

R¹¹ and R¹² each represents a substituent

m represents an integer of 1-4, and

the other symbols have the same meanings as those mentioned above.


48. (Canceled).

49. (Original): The compound according to claim 25, wherein the cyclic group optionally with a substituent(s) represented by B is an aromatic ring.

50. (Canceled).

51. (Previously Presented): The compound according to claim 49, wherein the cyclic group is substituted with 1 or at least 2 substituents.

52. (Previously Presented): The compound according to claim 51, wherein the cyclic group with at least 2 substituents is



wherein B¹ represents a carbon ring of an aromatic ring,

R¹¹ and R¹² each represents a substituent,

m represents an integer of 1-4, and

the other symbols have the same meanings as those mentioned above.

53-60. (Canceled).

61. (Withdrawn-previously presented): A method for treatment and/or prevention of a disease due to constriction of blood vessels in a mammal, which comprises administering to a mammal an effective dose of the compound according to claim 10 or a pharmaceutically salt acceptable thereof.

62. (Withdrawn-previously presented): A method for inhibition of EDG-5 in a mammal, which comprises administering to a mammal an effective dose of the compound according to claim 10 or a pharmaceutically acceptable salt thereof.

63-70. (Canceled).